Pan L - Search Results

1

Computational-aided rational mutation design of pertuzumab to overcome active HER2 mutation S310F through antibody-drug conjugates.

Bai X, Xu L, Wang Z, Zhuang X, Ning J, Sun Y, Wang H, Guo Y, Xu Y, Guo J, Chen S, Pan L. Bai X, et al. Among authors: pan l. Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2413686122. doi: 10.1073/pnas.2413686122. Epub 2024 Dec 30. Proc Natl Acad Sci U S A. 2025. PMID: 39793038

2

Structure-Guided and Phage-Assisted Evolution of Therapeutic Antibodies to Reverse On-Target Point Mutation-Mediated Resistance.

Zhuang X, Chen S, Pan L. Zhuang X, et al. Among authors: pan l. Methods Mol Biol. 2024;2793:41-54. doi: 10.1007/978-1-0716-3798-2_3. Methods Mol Biol. 2024. PMID: 38526722

3

Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.

Lai J, Wang Y, Wu SS, Ding D, Sun ZY, Zhang Y, Zhou J, Zhou Z, Xu YC, Pan LQ, Chen SQ. Lai J, et al. Biomaterials. 2018 Sep;178:158-169. doi: 10.1016/j.biomaterials.2018.06.017. Epub 2018 Jun 15. Biomaterials. 2018. PMID: 29933102

4

High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates.

Liu W, Zhao W, Bai X, Jin S, Li Y, Qiu C, Pan L, Ding D, Xu Y, Zhou Z, Chen S. Liu W, et al. Among authors: pan l. Eur J Pharm Sci. 2019 Jun 15;134:81-92. doi: 10.1016/j.ejps.2019.04.015. Epub 2019 Apr 13. Eur J Pharm Sci. 2019. PMID: 30986472

5

Identification of an Activating Mutation in the Extracellular Domain of HER2 Conferring Resistance to Pertuzumab.

Zhang Y, Wu S, Zhuang X, Weng G, Fan J, Yang X, Xu Y, Pan L, Hou T, Zhou Z, Chen S. Zhang Y, et al. Among authors: pan l. Onco Targets Ther. 2019 Dec 30;12:11597-11608. doi: 10.2147/OTT.S232912. eCollection 2019. Onco Targets Ther. 2019. PMID: 31920346 Free PMC article.

6

Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.

Qiu CX, Bai XF, Shen Y, Zhou Z, Pan LQ, Xu YC, Zhao WB, Chen SQ. Qiu CX, et al. Bioconjug Chem. 2020 Dec 16;31(12):2767-2778. doi: 10.1021/acs.bioconjchem.0c00548. Epub 2020 Nov 25. Bioconjug Chem. 2020. PMID: 33237767

7

TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation.

Shen Y, Wei X, Jin S, Wu Y, Zhao W, Xu Y, Pan L, Zhou Z, Chen S. Shen Y, et al. Among authors: pan l. Asian J Pharm Sci. 2020 Nov;15(6):777-785. doi: 10.1016/j.ajps.2020.01.002. Epub 2020 Mar 5. Asian J Pharm Sci. 2020. PMID: 33363632 Free PMC article.

8

A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models.

Fan J, Zhuang X, Yang X, Xu Y, Zhou Z, Pan L, Chen S. Fan J, et al. Among authors: pan l. Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5. Signal Transduct Target Ther. 2021. PMID: 34475375 Free PMC article. No abstract available.

9

Emerging new therapeutic antibody derivatives for cancer treatment.

Jin S, Sun Y, Liang X, Gu X, Ning J, Xu Y, Chen S, Pan L. Jin S, et al. Among authors: pan l. Signal Transduct Target Ther. 2022 Feb 7;7(1):39. doi: 10.1038/s41392-021-00868-x. Signal Transduct Target Ther. 2022. PMID: 35132063 Free PMC article. Review.

10

Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance.

Zhuang X, Wang Z, Fan J, Bai X, Xu Y, Chou JJ, Hou T, Chen S, Pan L. Zhuang X, et al. Among authors: pan l. Nat Commun. 2022 Jul 30;13(1):4431. doi: 10.1038/s41467-022-32159-6. Nat Commun. 2022. PMID: 35907884 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,638 results

Search Page

Filters